HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High antitumor activity of pladienolide B and its derivative in gastric cancer.

Abstract
The antitumor activity of pladienolide B, a novel splicing inhibitor, against gastric cancer is totally unknown and no predictive biomarker of pladienolide B efficacy has been reported. We investigated the antitumor activity of pladienolide B and its derivative on gastric cancer cell lines and primary cultured cancer cells from carcinomatous ascites of gastric cancer patients. The effect of pladienolide B and its derivative on six gastric cancer cell lines was investigated using a MTT assay and the mean IC50 values determined to be 1.6 ± 1.2 (range, 0.6-4.0) and 1.2 ± 1.1 (range, 0.4-3.4) nM, respectively, suggesting strong antitumor activity against gastric cancer. The mean IC50 value of pladienolide B derivative against primary cultured cells from 12 gastric cancer patients was 4.9 ± 4.7 nM, indicative of high antitumor activity. When 18 SCID mice xenografted with primary cultured cells from three patients were administered the pladienolide B derivative intraperitoneally, all tumors completely disappeared within 2 weeks after treatment. Histological examination revealed a pathological complete response for all tumors. In the xenograft tumors after treatment with pladienolide B derivative, immature mRNA were detected and apoptotic cells were observed. When the expressions of cell-cycle proteins p16 and cyclin E in biopsied gastric cancer specimens were examined using immunohisctochemistry, positivities for p16 and cyclin E were significantly and marginally higher, respectively, in the low-IC50 group compared with the high-IC50 group, suggesting the possibility that they might be useful as predictive biomarkers for pladienolide B. In conclusion, pladienolide B was very active against gastric cancer via a mechanism involving splicing impairment and apoptosis induction.
AuthorsMomoko Sato, Naoki Muguruma, Tadahiko Nakagawa, Koichi Okamoto, Tetsuo Kimura, Shinji Kitamura, Hiromi Yano, Katsutaka Sannomiya, Takahiro Goji, Hiroshi Miyamoto, Toshiya Okahisa, Hiroaki Mikasa, Satoshi Wada, Masao Iwata, Tetsuji Takayama
JournalCancer science (Cancer Sci) Vol. 105 Issue 1 Pg. 110-6 (Jan 2014) ISSN: 1349-7006 [Electronic] England
PMID24635824 (Publication Type: Journal Article)
Copyright© 2013 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.
Chemical References
  • Antineoplastic Agents
  • Cyclin E
  • Cyclin-Dependent Kinase Inhibitor p16
  • Epoxy Compounds
  • Macrolides
  • pladienolide B
Topics
  • Aged
  • Aged, 80 and over
  • Animals
  • Antineoplastic Agents (therapeutic use)
  • Apoptosis (drug effects, genetics)
  • Cell Line, Tumor
  • Cyclin E (genetics)
  • Cyclin-Dependent Kinase Inhibitor p16 (genetics)
  • Epoxy Compounds (therapeutic use)
  • Female
  • Humans
  • Macrolides (therapeutic use)
  • Male
  • Mice
  • Mice, SCID
  • Middle Aged
  • RNA Splicing (drug effects, genetics)
  • Random Allocation
  • Stomach Neoplasms (drug therapy, genetics)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: